In two outbreaks of food-borne botulism in France, Clostridium botulinum type A was isolated and characterized from incriminated foods. Botulinum neurotoxin type A was detected in the patients' sera by mouse bioassay and in vitro endopeptidase assay with an immunocapture step and identification of the cleavage products by mass spectrometry.
B
otulism is a rare disease in France (annual incidence of 0.2 to 0.5 per million inhabitants), consisting mainly of type B food-borne botulism due to the consumption of homemade canned foods or pork products or, in some cases, commercial food preparations (4, 15) . However, severe outbreaks of type A botulism have been identified in recent years in different areas of France (13, 15, 17, 18) . Detection of botulinum neurotoxin (BoNT) in biological samples, mainly in serum, is the most direct way to confirm a diagnosis of botulism. Since the toxicity of BoNTs is extremely high, the mouse bioassay remains the standard method, because it is able to detect minute amounts of BoNT. But new in vitro methods are in development as alternatives to the mouse bioassay to provide information on toxicity within a matter of hours instead of days (3, 14) .
C. botulinum strains were isolated from food samples using egg yolk agar medium supplemented with D-cycloserine, sulfamethoxazole, and trimethoprim (14) . The bont gene was PCR amplified with overlapping primer pairs and sequenced (9) .
The immunocapture test was performed with protein G magnetic beads coupled to immunopurified rabbit polyclonal antiBoNT/A-Hc antibodies at 0.2 mg/ml as described previously (1) (Fig. 1A and B) . Five-microliter amounts of coated beads were incubated in 500 l of human serum or toxin preparation diluted in 500 l HEPES buffer containing 1 mg/ml bovine serum albumin (BSA) for 1 h at room temperature and washed three times in HEPES-BSA buffer. The beads were suspended in 25 l of reaction buffer containing the peptide substrate as described in reference 2. The mixtures were incubated at 37°C for 4 h. Detection of the C-terminal (C-ter) and N-terminal (N-ter) peptides resulting from substrate cleavage was modified from Barr's protocol (2) . Briefly, 25 l of water containing 2% trifluoroacetic acid and 1 g/ml of internal standard as defined in reference 2 were added to the bead suspensions. After centrifugation, the supernatant (40 l) was injected into a liquid chromatography system coupled to a triple quadrupole mass spectrometer (LC-MS/MS). Chromatography was achieved on a Zorbax SB C 18 column (150 by 2.1 mm inner diameter) with a gradient elution of mobile phase A (water with 0.1% formic acid) and mobile phase B (acetonitrile with 0.1% formic acid). The mass spectrometer was a TSQ Quantum Ultra (Thermo Scientific, San Jose, CA) operated in the positive ion mode and coupled to the HPLC column via an electrospray interface. Successive dilutions of the cleaved C-ter peptide were injected into the LC-MS/MS system to check linearity and limit of detection (LOD). The ratio of the peak area of C-ter peptide to the coeluted internal standard, i.e., the normalized peak area, was monitored and found at 1 ϫ 10 Ϫ3 at the lowest detectable C-ter peptide dilution showing a signal-to-noise ratio of 10.
In vivo assays were performed as previously described (16) . In outbreak 1 (2008), two persons from northwest France with a generalized and complete paralysis were hospitalized in intensive care unit 1 day after eating industrially produced chicken enchiladas (Table 1 ) (13). They needed long-term intubation/ mechanical ventilation for 4 and 5 months, respectively. BoNT serotype A (BoNT/A) was detected in the serum of both patients by the mouse bioassay with estimated titers of 8 and 16 50% minimal lethal dose (MLD 50 )/ml. The remaining chicken and vegetable mix contained a high level of BoNT/A and a C. botulinum type A strain (Table 1 ). The isolated strain (2008-148) was initially identified as subtype A1 based on bont gene sequencing. However, the amino acid sequence identity of BoNT/A of this strain was 93.8% similar to that of strain Hall (subtype A1) and 94.3% similar to that of strain H04402 065 (subtype A5) (5). Strain 2008-148 is more closely related, though not identical, to subtypes A1 and A5 than to the other subtypes (Fig. 2) .
Outbreak 2 occurred in Corsica in 2010 and included 5 persons presenting signs of severe intoxication (Table 1) . Three patients required mechanical ventilation for 37 to 78 days, and a young person died from cardiac/respiratory failure (17) . The patients had consumed a salad prepared with homemade canned beans, which contained BoNT/A and a C. botulinum type A strain. The person who died had a toxin titer of 8 MLD 50 /ml, and neither BoNT/A nor C. botulinum was detected in two intestinal content samples ( Table 1) . The isolated C. botulinum strain (2010-969) from the salad was classified as subtype A2 by bont sequencing (100% sequence identity with strain Mascarpone). It is assumed that food contamination reflects the prevalence of C. botulinum types in the environment where the food is prepared (6) . This is consistent with the fact that C. botulinum A2 is frequent in southern Italy (8) and that the contaminated food from Corsica, which is close to Italy, also contains a subtype A2 strain.
The Endopep-MS assay was reported to be a sensitive and reliable method of BoNT/A detection and identification in biologi-cal samples (2, 10, 12) and could be an alternative in vitro method instead of the classical mouse bioassay. An immunocapture step was included to increase the sensitivity of the Endopep-MS assay, as previously found (7, 12) . To avoid any loss of BoNT/A enzymatic activity with anti-L antibodies (11), we used polyclonal antibodies raised against the BoNT/A-Hc domain and further purified by immunoaffinity with the recombinant antigen protein (Fig. 1A and B) .
The sensitivity of the Endopep-MS assay combined with immunocapture was determined with BoNT/A diluted in aqueous buffer or in human serum in comparison with the mouse bioassay. As shown in Table 2 , both methods gave roughly equivalent levels of sensitivity with samples containing limiting amounts of BoNT/A. In the dilutions containing approximately 1 MLD 50 , the toxin was detected by the immunocapture-Endopep-MS assay with a normalized C-ter peptide signal of around the signal at the LOD (Table 2 ). All the 7 patients' sera which were found to contain BoNT/A by mouse bioassay, with estimated titers ranging from 4 to 16 MLD 50 /ml (2 to 8 MLD 50 /mouse) ( Table 1) , yielded a positive signal in immunocapture-Endopep-MS assay from around 1 to 7 times the signal at LOD (Table 1 and Fig. 1) . However, the results with naturally contaminated sera did not parallel the mouse bioassay titration (Table 1) . This could be due to several explanations: the incremental nature of the mouse results working above the LOD but below the limit of quantification, different toxin subtypes/variants, patient's serum limitations, etc. The immunocapture-Endopep-MS assay was specific, since any of the 5 control sera yielded a positive signal, and the polyclonal antibodies raised against BoNT/A1 Hc were able to efficiently capture both BoNT/A2 and BoNT/A1-A5. Another advantage of the in vitro assay is that it allows unambiguous differentiation between botulism and autoimmune neuropathies like Guillain-Barre syndrome. Indeed, the initial clinical symptoms of Guillain-Barre syndrome can be similar to those of botulism (19) , and in our experience, sera from certain of these patients induce respiratory distress in mice, which can be confused with symptoms following injection of BoNT. Indeed, an immunocapture-Endopep-MS for BoNT/B has been found useful to differentiate type B botulism from Guillain-Barre syndrome (7). a Culture supernatant of strain Hall calibrated to an estimated titer of 50 MLD 50 /ml was serially 2-fold diluted in phosphate-buffered saline (PBS)-gelatin (BoNT/A in aqueous buffer). One volume of a pool of human serum was mixed with 1 volume of C. botulinum type A culture supernatant, and then serial 2-fold dilutions in PBS-gelatin were performed (BoNT/A in human serum). Mice were injected intraperitoneally with 0.5 ml of toxin dilutions. The estimated MLD 50 per mouse according to each dilution of the starting toxin preparation is indicated in the second column. Results are expressed as the number of dead mice versus total number of challenged mice and are from three independent experiments. Immunocapture was performed with 0.5 ml of each preparation or dilution and then subjected to LC-MS. The results are expressed as the mean normalized C terminus peptide peak areas (SRM transition, 324.8/422.2) Ϯ standard deviations and are from three independent experiments. BLD, below limit of detection.
